Global Antimicrobial Resistance Laboratory and Response Network Performance Measurement Tool Crosswalk
Change # |
Form # |
QID |
Section Name |
Original Question |
New Question |
Change |
Justification |
1. |
N/A |
N/A |
Tool Instructions |
Please complete the tool using information that will be included in your organization's Year 3 performance narrative submission. Please answer as many questions as possible.
FORM 1: RECIPIENT INFORMATION - This form is to be completed at recipient level. Please complete based on project activities during the current budget period BP4. If any recipients are implementing multiple projects, they will be asked to kindly complete Sections 1-3 of this form for each additional Strategy 2-5 projects. - For any questions where recipient is not aware or unsure of response, please enter ‘N/A’ or ‘Unknown’ where applicable |
Please complete the tool using information that will be included in [recipname_bp4]'s performance narrative submission for the current reporting period.
FORM 1: RECIPIENT INFORMATION Please answer the following questions related to [recipname_bp4]’s Global AR Lab and Response Network project implementation, laboratory activities, and workforce development activities during the current reporting period. This form is to be completed at the recipient level. Any recipients implementing multiple projects during the current reporting period are kindly requested to complete FORM 1 for each Strategy 2-5 project(s). For any questions where recipient is not aware or unsure of response, please enter ‘Does not apply’ where applicable |
|
|
2. |
N/A |
N/A |
Entire tool |
Present tense used in some questions |
Past tense for all questions in tool |
|
|
3. |
1 & 2 |
N/A |
N/A |
The reporting period for responses was specified in previous version |
All reporting period references changed to “during this reporting period” to allow for specifying at a later time |
|
|
4. |
1 |
5. |
Recipient Information |
Please select the pathogen(s) of interest for this project: (select all that apply)
|
5. Select the pathogen(s) of interest for this project: (select all that apply)
|
|
|
5. |
1 |
3. |
Project Implementation |
1.i. What is the number of sites (laboratories, hospitals, healthcare facilities, etc.) that were supported as part of the project? Please answer for each country. 1.ii. How many sites received direct material support (i.e., lab reagents/diagnostics, other lab equipment, IT material, printed SOPs, etc.) from this organization during this budget period as part of the project? Please answer for each country. |
3. How many sites (laboratories, hospitals, healthcare facilities, etc.) were supported as part of the project across all countries during this reporting period?
N/A |
|
|
6. |
1 |
2., 2.a., 2.b., 2.b.i. & 2.b.ii. |
Project Implementation |
1.a. Please select the countries in which this project was implemented during BP3.
2. Is this project contributing to achieving the goals of a country’s national action plan (NAP) on antimicrobial resistance?
2.a/b. If yes, please list all countries and describe supporting activities of NAP (Open-ended)
2.c. If no, please list barriers to participation and/or support of the NAP (Open-ended) |
2. Select the countries this project was implemented in during this reporting period. 2.a. In [selected country], did this project directly collaborate with: (select all that apply)
2.b. Did this project contribute to this country’s NAP? (Y/N/DK/Does not apply) 2.b.i. If Yes, please describe how project activities contributed to supporting the country’s NAP 2.b.ii. If No, please list barriers to participation and/or support of the NAP |
|
|
7. |
1 |
4. |
Project Implementation |
N/A |
Select the phase that best describes this partner’s and/or site’s implementation, for the current reporting period: a) Exploration; b) Initiation; c) Initial Implementation; d) Full Implementation and Maintenance; e) Expansion/ Scale-Up; f) Reduction/ Scale-Down g) Close Out |
|
|
8. |
1 |
5. |
Project Implementation |
3. List any major product(s) (e.g., SOPs, job aids, manuscripts, posters, trainings, etc.) developed within this budget period and specify location (if applicable).
If none, enter N/A |
5. What major product(s) (e.g., SOPs, job aids, manuscripts, posters, trainings, etc.) were developed within this budget period? How many of each were developed? (Select all that apply)
Does not apply 5.a. Provide links to any major products developed within this reporting period that are publicly available. |
|
|
9. |
1 |
6. |
Project Implementation |
4. Have any CDC Subject Matter Experts (SMEs) reviewed the major products listed in question #5? a) Yes b) No c) Don’t Know d) Does not apply |
6. Did any CDC Subject Matter Experts (SMEs) review the major products listed in question #5? a) Yes, all major products were reviewed by CDC SMEs b) Yes, some major products were reviewed by CDC SMEs ( 6.a.) c) No, major product were not reviewed by CDC SMEs ( 6.a.) d) Don’t know e) Does not apply |
|
|
10. |
1 |
7. |
Project Implementation |
5. What strategies or activities has [pilot_recipname] implemented to address sustainability of the efforts and progress made with this project beyond the current budget period? |
7. How did [recipname_bp4] ensure sustainability of project activities, during this reporting period? (Consider all project activities, including those related to workforce development, laboratories, and surveillance and response.) |
|
|
11. |
1 |
N/A |
All Sections |
Please use this space to include any additional information related to implementation of this project (Respondents are prompted to add additional information or context at the end of each section) |
Please use this space to include any additional information related to [section name] for this project, including notable successes or challenges, during this reporting period? |
|
|
12. |
1 |
N/A |
Laboratory Activities |
Section 3 Instructions: Please answer the following questions based on this organization’s current laboratory enhancement activities for this Global AR Lab & Response Network project. Please use information that will be included in this organization’s Year 3 performance narrative submission and please be as thorough as possible. |
Section 3 Instructions: Please answer the following questions related to laboratory activities for [recipname_bp4]’s Global AR Lab and Response Network project during the current reporting period. We recommend using information that will be reported in the performance narrative submission. |
|
|
13. |
1 |
1. |
Laboratory Activities |
1. Is there a national or central laboratory which performs quality assurance testing for this project?
|
1. Does the recipient directly provide or collaborate with another organization to provide external quality assessment (EQA) to laboratories for this project?
|
|
|
14. |
1 |
1.a. |
Laboratory Activities |
1.a. If yes:
|
1.a. If yes: Describe EQA; organization(s) providing EQA; pathogen(s) included; number of isolates or samples submitted; and frequency), by country List as follows: 1. [Country A Name], [Number of laboratories], [details about EQA]; 2. [Country B Name], [Number of laboratories], [details about EQA]; 3. [Country C Name], [Number of laboratories], [details about EQA]; etc. |
|
|
15. |
1 |
2.-6 |
Laboratory Activities |
What is the total number of labs where training or other activities for performing [TEST] were implemented? |
How many laboratories received training or support for [TEST METHOD] during this reporting period?
|
|
|
16. |
1 |
5. & 6. |
Laboratory Activities |
5.a.) What is the total number of labs where training or other activities for performing antimicrobial susceptibility testing (AST) were implemented?
6.a.) What is the total number of labs at which training or other activities for performing whole genome sequencing (WGS) were implemented? |
5. How many laboratories received training or support for antimicrobial susceptibility testing (AST), including antifungal susceptibility testing (AFST), of any pathogen(s) during this reporting period? 6. How many laboratories received training or support for sequencing of any pathogen(s) during this reporting period? |
|
|
17. |
1 |
N/A |
Workforce Development Activities |
Section 2 Instructions The following questions cover current education and training activities for different personnel targeted by this Global AR Lab & Response Network project. Do not answer questions based on future efforts, only established or current opportunities during budget period 3. |
Section 2 Instructions: Please answer the following questions related to Workforce Development activities for [recipname_bp4]’s Global AR Lab and Response Network project during the current reporting period. We recommend using information that will be reported in the performance narrative submission. |
|
|
18. |
1 |
1. |
Workforce Development |
N/A |
|
|
|
19. |
1 |
N/A |
Workforce Development Activities |
Please select the type of personnel that received training from this organization (can be in collaboration with partners): (select all that apply) a) Laboratory b) Epidemiologist/Data Manager c) Healthcare Worker d) Field-based personnel (community interviewer) e) MOH/NPHL leadership f) Other (please specify): ____________ g) Trainings that were performed did not document types of personnel in attendance (please provide disaggregated number of personnel) h) No personnel received training during this budget period (end of form) |
2. Please select the type of personnel that received training from this organization (can be in collaboration with partners): (select all that apply) a) Epidemiologist/Data Managers b) Healthcare Workers c) Laboratory personnel d) MOH/NPHL leadership e) Other ( 2.e., then i. &ii.) f) Personnel type(s) were not captured g) No personnel received training during this budget period ( skip 2-6) |
|
|
20. |
1 |
2. |
Workforce Development Activities |
2. Are there any other partnerships (e.g., universities, hospitals, etc.) that provide mentorship for [insert personnel type] personnel targeted by this project? a) Yes (2.a.) b) No c) Don’t Know 2.a. If yes, please list these partnerships. |
N/A |
|
|
21. |
1 |
|
Workforce Development Activities |
4.a. If yes, i. Does the curriculum leverage a Train-the-Trainer model? (Yes/No) ii. What entity is responsible for facilitating the curriculum? (Open ended) iii. What assessments were conducted to ensure trainings addressed knowledge gaps? (Open ended) |
iv.. Do the trainings use a Train-the-Trainer model?
v. What assessments were conducted to ensure trainings objectives were met? |
|
|
22. |
2 |
N/A |
N/A |
Form 2 Instructions: The following questions are related to project implementation with partners as well as referral network and surveillance practices at EACH hospital, health care facility (HCF) and/or laboratory that is participating in [name of organization autofill]'s Global AR Lab & Response Network project. Please complete FORM 2 for EACH partner, HCF/hospital, or laboratory. Recipients with projects in multiple countries or engaged with multiple partners or HCFS/hospitals/laboratories will be asked to specify country and partner/facility name on each form. |
Form 2 Instructions: Please answer the following questions related to project implementation with partners as well as referral network and surveillance practices for EACH hospital, health care facility (HCF) and/or laboratory that is participating in Global AR Lab and Response Network project during the current budget period. We recommend using information that will be reported in the performance narrative submission. Please complete FORM 2 for EACH partner, HCF/hospital, and/or laboratory. Recipients with projects in multiple countries or engaged with multiple partners or HCFS/hospitals/laboratories will be asked to specify country and partner/facility name on each form. For any questions where recipient is not aware or unsure of response, please enter ‘Does not apply’ where applicable. |
|
|
23. |
2 |
2.-6. |
Partner or Laboratory Site Information |
1.a. Is this partner a laboratory or healthcare facility with lab?
2.a. Is this lab or healthcare site part of an academic institution? Y/N 2.b. Is this lab or healthcare site part of a private organization? Y/N **Alternative 2. Select the option that best describes this partner: (If No selected above)
|
5.a. Is this lab or healthcare site part of an academic institution? Y/N 5.b. Is this lab or healthcare site part of a private organization? Y/N **Alternative 5. If answered “No” to question 4., Select the option that best describes this partner: |
|
|
24. |
2 |
6. |
Partner or Laboratory Site Information |
N/A |
(same answer options as QID 5 in Form 1) |
|
|
25. |
2 |
7. |
Project Implementation |
|
|
|
|
26. |
2 |
2. |
Project Implementation |
N/A |
2. What type of assistance did [partr1_projsite] receive during this reporting period? a) Financial assistance only b) Technical assistance only c) Financial and technical assistance d) Does not apply |
- Question added about type of assistance provided to project site
|
|
27. |
2 |
3. |
Project Implementation |
5. Project contribution(s) made by this partner (e.g., equipment and supplies procured, trainings provided, isolates collected and submitted, etc.): |
3. What contribution(s) did [partnr1_projsite] make for the project during this reporting period? (select all that apply) a) Epidemiological data collection, management, and reporting b) Facilitation of or participation in meetings, trainings, or workshops c) Laboratory testing d) Project coordination e) Sample collection f) Sample submission, including storage, handling, and transport g) Technical assistance to other project sites h) Work product development (e.g., SOPs, publications, etc.) i) Other (Please specify) j) N/A
|
|
|
28. |
2 |
1.a. |
Laboratory Activities |
N/A |
If no, please list barriers to this site’s participation in a laboratory network or referral network. |
|
|
29. |
2 |
8. |
Laboratory Activities |
(Only asked of laboratories or HCFs with lab) a) Yes b) No (end of form) c) Don’t know (end of form) d) Other (Please specify): __________________ |
N/A |
|
|
30. |
2 |
2.-8. |
Laboratory Activities |
Which of the following testing methods are routinely performed at this site/laboratory? Culturing – only in context of project pathogen(s) of interest
AST – only in context of project pathogen(s) of interest
Phenotypic – only in context of project pathogen(s) of interest
Genotypic – only in context of project pathogen(s) of interest
WGS – only in context of project pathogen(s) of interest What type of sequencing are you doing?
What instrument(s) are you using?
ii. Total testing volume (during budget period) Open ended iii. Total number of personnel that received training in testing method Integer
Sequencing only v. Total number of personnel trained to perform bioinformatics analysis of WGS data Integer vi. Describe the bioinformatics pipelines being utilized to analyze data Open ended |
2.-8. Select testing methods performed on project pathogen(s) of interest (Select all that apply).
2. Culture 3. Antimicrobial Susceptibility Testing (AST or ASFT) (e.g., E test, disk diffusion, broth microdilution) 4. Phenotypic Testing (e.g., MALDI-TOF, VITEK 2, API, etc.) 5. Genotypic Testing (e.g., PCR) 6. Sequencing (e.g., WGS, short-read Illumina, long-read ONT, direct amplicon sequencing, NGS, etc.) 7. Other (Please specify):_______________ 8. Unknown ( if only Unknown selected, skip to 9.)
2.i.-7.i. For each testing method selected, select the specific tests routinely performed on project pathogen(s) of interest (Select all that apply)
2.i. Culturing – only in context of project pathogen(s) of interest
3.i. AST – only in context of project pathogen(s) of interest
4.i. Phenotypic – only in context of project pathogen(s) of interest
5.i. Genotypic – only in context of project pathogen(s) of interest
6.i. Sequencing – only in context of project pathogen(s) of interest What type of sequencing are you doing?
7.i. Other – only in context of project pathogen(s) of interest Please describe the testing method (Open-ended) 2-7.ii. What was the total testing volume for the pathogen(s) of interest for this testing method during this reporting period? Integer 2-7.iii. How many personnel received training in this testing method during this reporting period? Integer
6.iv. What [sequencing] instrument(s) are used?
6.v. How many personnel were trained to perform bioinformatic analysis of sequencing data during this reporting period? Integer 6.vi. Please name the bioinformatics pipelines that were utilized to analyze sequencing data. Open ended |
- Additional answer options provided, and others removed in follow up questions for each testing method routinely performed - Changed numbering scheme for easier data management and navigation of the tool - All sequencing-specific sub-questions (6.iv., 6.v., 6.vi.) are now grouped together in the tool - Alphabetized options to help respondents more quickly select appropriate responses - Some overall wording changes to ensure accurate interpretation of questions
|
|
31. |
2 |
N/A |
Laboratory Activities |
10. Does this site have a program or any activities that focus on retaining staff with institutional and technical knowledge once they are trained on any of the testing methods listed previously? a) Yes ( 10.a.) b) No c) Don’t know d) Does not apply
10.a. If yes, please describe: |
N/A |
|
|
32. |
2 |
9. |
Laboratory Activities |
11. Describe how laboratory data and results are managed and what platform (e.g., Laboratory Information Management System (LIMS), etc.) is used for data management at this laboratory/facility. a) Data is managed manually b) Laboratory Information Management System (LIMS) c) Sample Management System d) N/A for this reporting period e) Unknown f) Other (please specify): |
9. How are laboratory samples and data primarily managed? a) Laboratory Information Management System (LIMS) - please specify b) Microsoft Excel c) Paper d) Other – please specify e) N/A f) Unknown
|
|
|
33. |
2 |
12. |
Laboratory Activities |
12. If applicable, describe data management in the field or at point of collection (e.g., environmental surveillance sites, etc.) as well as in the lab. Open ended |
N/A |
|
|
34. |
2 |
10. & 10.a. |
Laboratory Activities |
13. Is regular external quality assessment performed for AR testing at this project’s participant laboratories? a) Yes ( 13.a.) b) No c) Don’t Know d) Does not apply 13.a. If yes, please describe the type and frequency of these EQA activities (e.g., PulseNet EQA, 2 bacterial specimens/ year for identification and AST, etc.) |
10. Was the [partnr1_projsite] participating in any EQA programs for the project’s pathogen(s) of interest? (NOTE: answer yes even if EQA provided separately from project) a) Yes ( 10.a.) b) No c) Don’t know d) Does not apply 10.a. Describe EQA (organization[s] providing EQA; pathogens included; number of isolates or samples submitted; and frequency) List as follows: 1. [Organization providing EQA], [pathogen(s) included], [number of isolates or samples submitted], and [frequency]; 2. [Organization providing EQA], [pathogen(s) included], [number of isolates or samples submitted], and [frequency]; |
|
|
35. |
2 |
1.a. |
Surveillance and Response Activities |
1. Are epidemiological data elements collected with samples tested under this project? a) Yes ( 1.a.) b) No ( 1.b.) c) Don’t know 1.a. If yes, please i. Describe what data elements are being collected. (Open ended) ii. List each of the sites collecting these elements within the project and indicate if the information is shared with public health for decision making. (Open ended) |
1. Were epidemiological data elements collected with samples tested as part of this project? a) Yes ( 1.a.) b) No ( 1.b.) c) Don’t know 1.a. If yes, describe what data elements are being collected and, if applicable, how they are used for public health decision-making. |
- Small wording edit in QID 1 - QIDs 1.a.i. and 1.a.ii. consolidated into question 1.a.
|
|
36. |
2 |
2., 2.a.-2.e. |
Surveillance and Response Activities |
2. Are the collected data for this project (e.g., phenotypic, genotypic, and NGS) integrated into subnational, national, or global databases? a) Yes ( 2.a.) b) No ( 2.b.) c) Don’t Know 2.a. If yes, please i. Describe what database(s) the data were reported to. Please list all. (Open ended)
ii. Indicate the frequency of data sharing with national-level decision makers (e.g., MoHs, NPHIs, etc.)? a) Daily b) Weekly c) Bi-weekly d) Quarterly e) Annually f) Other (please specify): 2.b. If no, please list any barriers to data integration. (Open ended) |
2. Were the data (e.g. laboratory, epidemiological, etc.) collected for this project submitted to subnational, national, or global databases? (select all that apply) a) Global ( 2.a.) b) National ( 2.b.) c) Subnational ( 2.c.) d) Other ( 2.d.) e) Not submitted to a database ( 2.e.) f) N/A g) Don’t Know
2.a.-2.d. Sub-questions i. and ii. will iteratively repeat for each of the selections above a-d. i. How often were data submitted to the database(s) a) Daily b) Weekly c) Bi-weekly d) Quarterly e) Annually f) Other (please specify): ii. Please list and describe database(s) that data were reported to (Open-ended) List as follows:
2.e. If no, list any barriers to data submission or sharing. (Open ended)
|
|
|
37. |
2 |
3. & 3.a. |
Surveillance and Response Activities |
3. Have any alerts or findings from the lab or facility required a local response (e.g., within facility or local area, data sharing, PPS, etc.)? a) Yes ( 3.a.) b) No c) Don’t Know 3.a. If yes, please list the entities involved, response activities, and how data was shared. (Open ended) |
3. Did any findings from [partnr1_projsite] lead to an alert notification during this reporting period? a) Yes ( 3.a.) b) No c) Don’t know d) Does not apply 3.a. If yes, describe the alert, including why an alert was needed, entities and levels of health system involved, and how data were shared. List as follows: 1. [Alert 1: description and justification], [level(s) of health system involved], [entities involved], and [describe how data were shared]; 2. [Alert2: description and justification], [level(s) of health system involved], [entities involved], and [describe how data were shared];
|
|
|
38. |
2 |
4., 4.a., & 4.b. |
Surveillance and Response Activities
|
4. Have any alerts or findings from the lab or facility been detected which required a sub-national or national response (e.g., new organism/type of resistance or large outbreak)? a) Yes ( 4.a.) b) No 4.a. If yes, please list the entities involved, response activities, and how data was shared. (Open ended)
|
4. Did any findings from [partnr1_projsite] led to the detection of an outbreak that required a response? a) Yes ( 4.a.) b) No c) Don’t know d) Does not apply 4.a. What level(s) of the health system were involved in the response? (select all that apply) a) Global b) National c) Subnational d) Other e) Don’t Know 4.b. Describe the outbreak and response activities, including entities and levels of health system involved, List as follows: 1. [Outbreak 1: description of outbreak and response activities], [entities involved], and [level(s) of health system involved] 2. [Outbreak 2: description of outbreak and response activities], [entities involved], and [level(s) of health system involved] |
|
|
39. |
2 |
N/A |
Laboratory Activities & Surveillance and Response Activities |
Original Section Names:
Section 2: Laboratory Network Activities
Section 3: Surveillance Activities |
Section 2: Laboratory Activities
Section 3: Surveillance and Response Activities |
|
|
| File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
| Author | Tavitian, Stephanie Victoria (CDC/NCEZID/DHQP/OD) |
| File Modified | 0000-00-00 |
| File Created | 2025-08-13 |